Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

Cardiol Therapeutics is supported by a credible clinical and commercial thesis because the peer-reviewed MAVERIC-Pilot study showed rapid, durable symptom relief, meaningful CRP reductions, and an annualized pericarditis event rate falling from 5.8 to 0.9 during participation, suggesting real anti-inflammatory activity in a difficult-to-treat population. The lower-than-expected blinded event rate in the Phase III MAVERIC trial creates some uncertainty, but the decision to expand enrollment to up to 150 patients and push topline results to mid-2027 indicates the program is still generating enough signal to preserve statistical power. With eligibility resembling high-relapse withdrawal populations and CardiolRx positioned as an oral, steroid-sparing option before or after injectable IL-1 blockers, the company has a differentiated path to value creation.

Cardiol Therapeutics is viewed negatively because the long-term rilonacept data suggest recurrent pericarditis is highly relapse-prone, with 75% recurrence in RHAPSODY extension patients and 82% recurrence in Cleveland Clinic patients after cessation, making a meaningfully lower placebo recurrence rate in MAVERIC difficult to justify without stronger evidence. The company’s outlook also remains constrained by a high-risk pipeline, as CardiolRx is assigned only a 70% probability of success in recurrent pericarditis and just 20% and 10% for acute myocarditis and heart failure, respectively, while commercialization and regulatory execution remain uncertain. Although it has cash on hand to fund operations into 3Q27, the stock’s proximity to $1 raises delisting risk, and the valuation relies on a 13.4% WACC and an 11.0x exit multiple that may prove demanding.